Global MicroRNA Industry Report 2022-2027 with Profiles from Thermo Fisher Scientific, Horizon Discovery, QIAGEN, BioGenex, and GeneCopoeia, among others –

DUBLIN–(BUSINESS WIRE)–The “MicroRNA Market – Growth, Trends, Impact of COVID-19, and Forecast (2022-2027)” report has been added to from offer.

The global microRNA market is expected to grow with a CAGR of 15.6% during the forecast period (2022-2027).

The COVID-19 pandemic has impacted healthcare systems globally and disrupted usual care in many healthcare settings, exposing vulnerable cancer patients to significant risk. In addition to the vaccinations against SARS-CoV-2 infection that have been approved, miRNAs are proving to be a potential alternative to combat this new virus. Expression of these miRNAs, on the other hand, is useful for detecting SARS-CoV-2 infection.

According to the National Center for Biotechnology Information, 2021, titled “The role of miRNAs in COVID-19 disease”, various miRNAs bind to the SARS-CoV-2 genome and limit its post-transcriptional expression, reducing the severity of COVID-19 disease. Moreover, among all miRNAs, miR-21-3p is found to have the best binding to the human coronavirus genome. Due to the increase in COVID-19 infection, the demand for effective treatment is increasing, which further increases the demand for next-generation sequencing and miRNA sequencing technologies.

According to an article published by the National Center for Biotechnology Information, 2020, titled “A new approach for microRNA treatment of COVID-19”, miRNAs have been found to perform critical functions during viral infection, thereby reducing the burden on health systems during a pandemic. Therefore, COVID-19 is having a positive impact on the microRNA market.

Factors propelling the growth of the microRNA market are increasing prevalence of chronic diseases, increasing incidence and prevalence of COVID-19 globally, advancement and adoption of next generation sequencing methods and their applications in various fields, and the increasing adoption of microRNAs as a biomarker.

Rising prevalence of chronic diseases such as cancer, cardiovascular diseases, diabetes, etc., and rare diseases are the major factors driving the market growth over the forecast period. For example, according to the American Cancer Society, approximately 36,000 new cases of cancer occurred in Wisconsin, United States, in 2021. According to Rare Disease Day, rare diseases are estimated to affect nearly 3.5 % to 5.9% of the world’s population in 2020. with more than 300 million people living with one or more of the more than 6,000 rare diseases identified worldwide.

Furthermore, the adoption of miRNA instruments and consumables should be facilitated by extensive research activities aimed at determining the possible functions of microRNAs (miRNAs) in the development of new treatments for a variety of disorders. For example, in June 2020, researchers in Munich revealed that a specific microRNA helps preserve endothelial integrity, thereby reducing the risk of atherosclerosis.

Additionally, the company’s initiatives in the development of microRNA tests and kits and strong funding from biotech companies are also contributing to the growth of the market. For example, Qiagen’s QIAseq miRNA Library Kit includes a gel-free miRNA sequencing library preparation from 1 ng of total RNA. It eliminates adapter dimers and unwanted RNA species for the highest fidelity and most efficient data, incorporates Unique Molecular Indexes (UMIs) for quantitative measurement of individual miRNA molecules, and connects directly to the Analysis Portal RNA-seq for human, mouse and rat samples. Similarly, in February 2021, Aurora Science, an Italian biotech investment firm, funded $22.46 million to InterRNA Technologies, for the development of miRNAs.

However, microRNA safety and toxicity issues are likely to hamper the market growth over the forecast period.

Main market trends

  • Real-Time Polymerase Chain Reaction Expected to Dominate the Market

  • North America is expected to hold a significant market share

Competitive landscape

The microRNA market is moderately competitive with several players across the globe. In terms of market share, various major players currently dominate the market. With the increase in research and development activities, many regional players are expected to become part of the microRNA market during the forecast period. Some of the major market players are Thermo Fisher Scientific, Inc., Qiagen NV, Illumina, Inc., PerkinElmer, Inc., and Takara Bio, Inc.

Main topics covered


1.1 Study assumptions and market definition

1.2 Scope of the study




4.1 Market Overview

4.2 Market Drivers

4.2.1 Increase in the prevalence of chronic diseases

4.2.2 Increase investment in research and development

4.3 Market Constraints

4.3.1 MicroRNA Safety and Toxicity Issues

4.4 Porter’s Five Forces Analysis


5.1 By technology

5.1.1 Real-time polymerase chain reaction

5.1.2 Microgrid

5.1.3 Next Generation Sequencing (NGS)

5.1.4 Immunoassay

5.2 By request

5.2.1 Cancer

5.2.2 Immunological disorder

5.2.3 Infectious diseases

5.2.4 Cardiovascular disease

5.2.5 Neurological disease

5.2.6 Others

5.3 By the end user

5.3.1 Academic and research institutes

5.3.2 Biopharmaceutical companies

5.3.3 Contract research organizations

5.3.4 Diagnostic centers

5.4 Geography

5.4.1 North America

5.4.2 Europe

5.4.3 Asia-Pacific

5.4.4 Middle East and Africa

5.4.5 South America


6.1 Company Profiles

6.1.1 Thermo Fisher Scientific, Inc.

6.1.2 Horizon Discovery Ltd.

6.1.3 QIAGEN

6.1.4 BioGenex

6.1.5 GeneCopoeia, Inc.

6.1.6 NanoString

6.1.7 Quantabio

6.1.8 SeqMatic LLC

6.1.9 OriGene Technologies, Inc.

6.1.10 Illumina, Inc.


For more information about this report visit

Source link